Anti-CD20 monoclonal antibody therapies in relapsing multiple sclerosis: A systematic review and meta-analysis of randomised controlled trials. (PubMed, Mult Scler Relat Disord) - Sep 25, 2026 - "Anti-CD20 mAbs confer consistent, clinically meaningful reductions in relapse rate and MRI disease activity. In the only direct head-to-head RCT, rituximab was non-inferior to ocrelizumab for MRI disease activity in newly diagnosed relapsing MS. Heterogeneity for MRI outcomes is strongly associated with trial design and warrants cautious interpretation; with few trials per stratum this attribution is associative rather than definitive. These agents represent a high-efficacy treatment class for relapsing MS."
Journal • Retrospective data • Review • CNS Disorders • Multiple Sclerosis
|
|
Abeer Alatawi; Ahmed Salem Al-Dhahi; Amirah Alatawi; Saleem Almaser
|